Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome-Case Report.
Aleksandra M KicińskaAneta StachowskaAnna KajdyTomasz H WierzbaRadosław B MaksymPublished in: Healthcare (Basel, Switzerland) (2023)
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Absent, impaired, or rare ovulation induces progesterone deficiency in the luteal phase, which is a critical problem in PCOS. A usual pattern of progesterone administration from a fixed and arbitrary pre-determined day of a menstrual cycle may preserve infertility but can easily be avoided. We present the case of a 29-year-old infertile woman who had been ineffectively treated for over two years. We introduced a line of therapy that was suited to her individual menstrual cycle by implementing biomarker recording. Supplementation based on a standardized observation of the basal body temperature (BBT) and cervical mucus stopped the vicious circle of absent ovulation and hyperandrogenism, restoring regular bleeding, ovulation cycles, and fertility. The implementation of a reliable fertility awareness method (FAM), accompanied by a standardized teaching methodology and periodic review of the observations recorded by the patient, validated through an ultrasound examination and plasma gonadotropins, estrogens, and progesterone concentrations, is key to achieving therapeutic success. The presented case is an example of a clinical vignette for many patients who have successfully managed to improve their fertility and pregnancy outcomes by applying the principles of a personalized treatment approach together with gestagens by recording their fertility biomarkers.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- case report
- pregnancy outcomes
- primary care
- healthcare
- quality improvement
- newly diagnosed
- end stage renal disease
- magnetic resonance imaging
- pregnant women
- chronic kidney disease
- ejection fraction
- estrogen receptor
- atrial fibrillation
- young adults
- replacement therapy
- metabolic syndrome
- mesenchymal stem cells
- patient reported outcomes
- combination therapy
- cell therapy